title: Melancholic/endogenous depression and response to somatic treatment and placebo.
abstract: OBJECTIVE
  The authors' goals were to examine the effects of somatic treatment and placebo in patients with and without endogenous/melancholic depression.
  
  
  METHODS
  Before entry into one of four trials of antidepressant drugs versus placebo, 231 patients were assessed as to whether they met Research Diagnostic Criteria for definite endogenous depression and/or DSM-III criteria for major depressive episode with melancholia. These patients were prospectively assessed for subsequent response to antidepressant treatment or placebo. Previous studies of the effect of endogenous/melancholic depression on treatment response were also reviewed.
  
  
  RESULTS
  Of the 76 patients with DSM-III melancholia given active medication, 41 (54%) had a complete or partial response, but only 10 (23%) of the 44 patients with melancholia given placebo had a complete or partial response. Of the 76 depressed patients without melancholia given active medication, 46 (61%) had a complete or partial response, and 15 (43%) of the 35 depressed patients without melancholia given placebo had a complete or partial response. Moderately depressed patients with DSM-III melancholia had a significantly better response to active medication than did severely depressed patients with melancholia and showed the greatest difference between response to active medication and response to placebo. The results of the review of previous studies of the effect of endogenous/melancholic depression on treatment response were mixed.
  
  
  CONCLUSIONS
  Depressed patients with melancholia were not particularly different from depressed patients without melancholia in their responses to antidepressant medication but did differ from patients without melancholia in their responses to active medication versus placebo, particularly if their depression was moderate and not severe. This suggests that patients with DSM-III melancholia may be unresponsive to nonsomatic treatments.
authors.affiliation: New York University School of Medicine, Brooklyn.
authors.forename: E D
authors.initials: ED
authors.lastname: Peselow
authors.forename: M P
authors.initials: MP
authors.lastname: Sanfilipo
authors.forename: C
authors.initials: C
authors.lastname: Difiglia
authors.forename: R R
authors.initials: RR
authors.lastname: Fieve
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D010091:Oximes / Q000627:therapeutic use; D017374:Paroxetine; D010880:Piperidines / Q000627:therapeutic use; D010919:Placebos; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D010091:Oximes; D010880:Piperidines; D010919:Placebos; D005473:Fluoxetine; D017374:Paroxetine; C020724:clovoxamine; D007099:Imipramine